Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DKK1 | O94907 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796149 | 0.89 | RAB9A (0.35) | DHFRRAB9ASMN1; SMN2AHRHSD17B10 | |
| SCHEMBL795840 | 0.86 | HDAC6 (0.44) | HDAC4HDAC1HDAC6 | |
| SCHEMBL17226428 | 0.85 | DKK1 (0.35) | MAOAMAOBRAB9ASMN1; SMN2DKK1 | |
| SCHEMBL795780 | 0.84 | SMN1; SMN2 (0.37) | DHFRRAB9ASMN1; SMN2AHRHSD17B10 | |
| SCHEMBL796424 | 0.84 | NPC1 (0.48) | MAOAMAOBRAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL795503 | 0.83 | NR1H4 (0.47) | DHFRRAB9ASMN1; SMN2HSD17B10MAPT | |
| SCHEMBL795549 | 0.83 | HDAC6 (0.41) | RAB9AMAPTNPC1HDAC4HDAC1 | |
| SCHEMBL795194 | 0.83 | KDM4E (0.42) | RAB9ANPC1KDM4EHDAC4HDAC1 | |
| SCHEMBL796054 | 0.82 | ALOX5AP (0.35) | DHFRRAB9ASMN1; SMN2AHRHSD17B10 | |
| SCHEMBL795514 | 0.81 | RAB9A (0.53) | DHFRMAOAMAOBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | DHFR 1553/4885MAOA 842/4885MAOB 583/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | DHFR 1553/4885MAOA 842/4885MAOB 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.